You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康寧傑瑞製藥(09966.HK)治療胃癌新藥臨床研究具可控安全性
阿思達克 09-05 08:29
康寧傑瑞製藥-B(09966.HK)公布,將於2022年歐洲腫瘤內科學會大會(2022年ESMO大會)上呈列KN046(一種抗PD-L1/CTLA-4雙特異性抗體)及KN026(一種HER2靶向雙特異性抗體)的研究結果。摘要將於歐洲中部夏令時間9月5日零時五分通過ESMO網站線上查閱及電子海報將於2022年ESMO大會(9月9至13日舉行)上展示。 據此,KN026聯合KN046治療既往未接受系統性治療的人表皮生長因子受體2(HER2)陽性胃癌/胃食管結合部癌(GC/GEJ)患者表現出卓越的療效和可控的安全性。 而KN046聯合含鉑雙藥化療作為非小細胞肺癌(NSCLC)一線治療顯示出良好的耐受性和頗具前景的臨床效果。兩個隊列的中位總生存期(OS)均超過2年,預計將在正在進行的III期臨床試驗中獲得更大人群的療效和安全性數據。 至於KN046在治療一線含鉑雙藥化療治療失敗的晚期NSCLC患者中顯示出良好的耐受性和療效,並在鱗狀和非鱗狀NSCLC中顯示出頗具前景的OS效益。此外,KN046在治療既往表皮生長因子受體酪氨酸激(酉每)抑制劑(EGFR-TKIs)治療失敗的表皮生長因子受體(EGFR)敏感性突變晚期NSCLC患者中顯示出良好的耐受性和療效。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account